What is Amgen's otezla — finite-lived intangible assets, net?

Amgen (AMGN) reported otezla — finite-lived intangible assets, net of $3.40B in Q4 2025.

What does otezla — finite-lived intangible assets, net mean?

The remaining accounting value of a drug's intellectual property after accounting for wear and tear or loss in value.

Amgen Otezla — Finite-lived intangible assets, net decreased by 29.2% to $3.40B in Q4 2025 compared to the prior quarter.

StatementSegment

CategoryEfficiency

SignalContext dependent

VolatilityStable

First reportedQ1 2025

Last reportedQ4 2025

A steady decline is expected due to amortization, but a sharp drop signals potential impairment or write-downs.

This represents the book value of intangible assets related to a specific product line, net of accumulated amortization...

Standard accounting metric for intangible assets found in the balance sheet notes of most public companies.

Metric ID: amgn_segment_otezla_finite_lived_intangible_assets_net

2 periods

	Q1 '25	Q4 '25
Value	$4.80B	$3.40B
QoQ Change	—	-29.2%

Range$3.40B – $4.80B

What is Amgen's otezla — finite-lived intangible assets, net?: Amgen (AMGN) reported otezla — finite-lived intangible assets, net of $3.40B in Q4 2025.
What does otezla — finite-lived intangible assets, net mean?: The remaining accounting value of a drug's intellectual property after accounting for wear and tear or loss in value.